Effective host immune responses are essential for the control of hepatitis C virus (HCV) infection and persistence of HCV has indeed been attributed to their failure. In recent years, several in vitro and in vivo experimental models have allowed studies of host immune responses against HCV. Numerous observations derived from these models have improved our understanding of the mechanisms responsible for the host's ability to clear the virus as well as of the mechanisms responsible for the host's failure to control HCV replication. Importantly, several findings obtained with these model systems have been confirmed in studies of acutely or chronically HCV-infected individuals. Collectively, several mechanisms are used by HCV to escape host immune responses, such as poor induction of the innate immune response and escaping/impairing adaptive immunity. In this review, we summarize current findings from experimental models available for studies of the immune response targeting HCV and discuss the relevance of these findings for the in vivo situation in HCV-infected humans.
IntroductionHepatitis C virus (HCV) is an enveloped RNA virus that belongs to the genus Hepacivirus within the family Flaviviridae. The positive-strand genome has a length of 9.6 kb and it encodes a polyprotein that is cleaved by viral and cellular proteases into 10 different proteins (reviewed by Moradpour et al., 2007). The structural proteins core, envelope protein 1 (E1) and E2 reside in the amino-terminal region of the polyprotein and they are the main constituents of infectious virus particles. The hydrophobic p7 protein together with non-structural protein 2 (NS2) are required for virion assembly. The serine-type protease residing in NS3 forms a stable complex with the NS4A cofactor and contributes to polyprotein cleavage. NS4B induces alterations of intracellular membranes, designated the membranous web, which is thought to be the site of viral RNA replication. NS5A is required for RNA replication and assembly and NS5B is the RNA-dependent RNA polymerase.HCV has a narrow host range and infects only humans and chimpanzees. It is estimated that~130 million people are persistently infected by HCV worldwide (reviewed by Shepard et al., 2005). Limited therapy options and the lack of a preventive vaccine aggravate this medical issue (reviewed by Lauer & Walker, 2001). Of note, the virus is able to establish persistence in approximately two-thirds of infected subjects and has thus become a major cause of chronic liver inflammation that can culminate in liver cirrhosis or even hepatocellular carcinoma (reviewed by Lauer & Walker, 2001). It is still not completely clear why successful immune responses allow only one-third of infected subjects to clear HCV. A major limitation when addressing this issue is the lack of an immunocompetent small animal model. Importantly, however, by using novel cell culture systems, some of these hurdles have now been overcome and first important insights into the intimate interaction between HCV and its host cell have b...